Inventor · disambiguated record
Marcia Belvin
Also filed as: BELVIN MARCIA
11 granted patents·30 pending applications·98 citations·filing 2001–2018
87Inventor score
Top patents by PatentIndex Score
41 records- 0196US9107926B2Mutant selectivity and combinations of a phosphoinositide 3-kinase inhibitor compound and chemotherapeutic agents for the treatment of cancerGENENTECH INC·Filed 2013·Granted Aug 18, 2015·28 cites·11 claims
- 0292US8247397B2Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of useBELVIN MARCIA·Filed 2008·Granted Aug 21, 2012·40 cites·34 claims
- 0391US8604014B2Combinations of phosphoinositide 3-kinase inhibitor compounds chemotherapeutic agents, and methods of useBELVIN MARCIA·Filed 2011·Granted Dec 10, 2013·26 cites·15 claims
- 0469US2008102070A1SCDs As Modifiers of the p53 Pathway and Methods of UseEXELIXIS INC·Filed 2007·Application pending·0 cites
- 0568US2008166709A1MARKs as Modifiers of the p53 Pathway and Methods of UseEXELIXIS INC·Filed 2007·Application pending·0 cites
- 0667US9532987B2Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseasesGENENTECH INC·Filed 2014·Granted Jan 3, 2017·1 cites·8 claims
- 0764US6924117B2Human RRP sequences and methods of useEXELIXIS INC·Filed 2001·Granted Aug 2, 2005·2 cites·5 claims
- 0863US2018280408A1Mutant selectivity and combinations of a phosphoinositide 3-kinase inhibitor compound and chemotherapeutic agents for the treatment of cancerGENENTECH INC·Filed 2018·Application pending·0 cites
- 0962US2003165966A1MSRAs as modifiers of the p53 pathway and methods of useFiled 2003·Application pending·0 cites
- 1059US2010275275A1HADHs as Modifiers of the p21 Pathway and Methods of UseEXELIXIS INC·Filed 2009·Application pending·0 cites
- 1156US2016045515A1Mutant selectivity and combinations of a phosphoinositide 3-kinase inhibitor compound and chemotherapeutic agents for the treatment of cancerGENENTECH INC·Filed 2015·Application pending·0 cites
- 1254US6972179B2RRP sequences and knockout mice and uses thereofEXELIXIS INC·Filed 2002·Granted Dec 6, 2005·0 cites·5 claims
- 1354US2013345217A1Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of useGENENTECH INC·Filed 2013·Application pending·0 cites
- 1454US2006160764A1LIMKs as modifiers of p53 pathway and methods of useEXELIXIS INC·Filed 2006·Application pending·0 cites
- 1553US8771942B2SCDs as modifiers of the p53 pathway and methods of useBELVIN MARCIA·Filed 2010·Granted Jul 8, 2014·0 cites·6 claims
- 1653US7049088B2PRMTs as modifiers of the p53 pathway and methods of useEXELIXIS INC·Filed 2002·Granted May 23, 2006·1 cites·2 claims
- 1752US8153384B2Marks as modifiers of the p53 pathway and methods of useFRIEDMAN LORI·Filed 2010·Granted Apr 10, 2012·0 cites·15 claims
- 1851US8268548B2MAP3Ks as modifiers of the p53 pathway and methods of useFRIEDMAN LORI·Filed 2007·Granted Sep 18, 2012·0 cites·12 claims
- 1951US2005181481A1HADHs as modifiers of the p21 pathway and methods of useEXELIXIS INC·Filed 2005·Application pending·0 cites
- 2051US2005227228A1Map3ks as modifiers of the p53 pathway and methods of useFRIEDMAN LORI·Filed 2002·Application pending·0 cites
- 2151US2005186200A1HADHs as modifiers of the p21 pathway and methods of useEXELIXIS INC·Filed 2005·Application pending·0 cites
- 2250US2003215849A1PDPK1s as modifiers of the p53 pathway and methods of useFiled 2003·Application pending·0 cites
- 2350US2003087266A1IGs as modifiers of the p53 pathway and methods of useFiled 2002·Application pending·0 cites
- 2450US2003219795A1SCDs as modifiers of the p53 pathway and methods of useFiled 2003·Application pending·0 cites
- 2550US2011159508A1GFATS as Modifiers of the P53 Pathway and Methods of UseEXELIXIS INC·Filed 2010·Application pending·0 cites
- 2647US6927022B2HADHs as modifiers of the p21 pathway and methods of useEXELIXIS INC·Filed 2002·Granted Aug 9, 2005·0 cites·21 claims
- 2747US2003013144A1HS2STs as modifiers of the p53 pathway and methods of useFiled 2002·Application pending·0 cites
- 2847US2005170344A1Chds as modifiers of the p53 pathway and methods of useFiled 2002·Application pending·0 cites
- 2947US2003165809A1MARKs as modifiers of the p53 pathway and methods of useFiled 2002·Application pending·0 cites
- 3047US2002192695A1PIBs as modifiers of the p53 pathway and methods of useFiled 2002·Application pending·0 cites
- 3147US2003027188A1SLC7s as modifiers of the p53 pathway and methods of useFiled 2002·Application pending·0 cites
- 3247US2003036076A1CADs as modifiers of the p53 pathway and methods of useFiled 2002·Application pending·0 cites
- 3346US2006121457A1Gfats as modifiers of the p53 pathway and methods of useEXELIXIS INC·Filed 2002·Application pending·0 cites
- 3444US2007286852A1Sppls as Modifiers of the P53 Pathway and Methods of UseEXELIXIS INC·Filed 2004·Application pending·0 cites
- 3541US2003036078A1P5CRs as modifiers of the p53 pathway and methods of useFiled 2002·Application pending·0 cites
- 3641US2007134732A1Lces as modifiers of the p53 pathway and methods of useEXELIXIS INC·Filed 2002·Application pending·0 cites
- 3741US2003138431A1LRRCAPs as modifiers of the p53 pathway and methods of useFiled 2002·Application pending·0 cites
- 3839US2003022209A1ADSLs as modifiers of the p53 pathway and methods of useFiled 2002·Application pending·0 cites
- 3937US2006024673A1Slc2as as modifiers of the p53 pathway and methods of useFRIEDMAN LORI·Filed 2002·Application pending·0 cites
- 4036US2006024665A1PRMTs as modifiers of the p53 pathway and methods of useFRIEDMAN LORI·Filed 2005·Application pending·0 cites
- 4134US2011086837A1Combinations of a pi3k inhibitor and a mek inhibitorGENENTECH INC·Filed 2010·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →